Even though lower price cards may help ease the load of superior drug fees from the short-term, they do not handle the systemic troubles driving up prescription selling prices during the U.S. Broader plan modifications could deal with the basis leads to of increasing drug rates, including not enough transparency in pricing and the job of intermedia